Irina Pivneva
 
                    Education
Ph.D., experimental psychology and cognitive neuroscience, McGill University; B.A., psychology, Concordia University; B.A., modern languages and literature, University of Northern Iowa
Summary of Experience
Dr. Pivneva specializes in health economics and outcomes research (HEOR), with a focus on real-world evidence (RWE) and the application of machine learning algorithms in health care. She has extensive experience with studies assessing the incidence and prevalence of diseases; the risks and benefits of medications; treatment patterns; comorbidity profiles; health resource utilization; direct medical and indirect productivity costs using a variety of study designs, data sources, and methodologies involving health insurance claims databases; panel- and site-based medical chart reviews; electronic medical records (EMRs); primary surveys for evidence generation; clinical trial data; gene replacement therapies; time and motion studies; and the use of machine learning techniques. Her clinical areas of expertise include oncology; dermatology; autoimmune disorders; renal disorders; mental health disorders; and nervous system disorders, including hereditary and degenerative disorders of the central nervous system. Dr. Pivneva has published studies in a number of peer-reviewed journals.
- 
                                                        Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based StudyAmerican Journal of Ophthalmology. 2019 Feb;198:181-192 
 2024Dana R, Bradley JL, Guérin A, Pivneva I, Evans AM, Stillman IÖ 
- 
                                                        Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, CanadaAmerican Journal of Clinical Dermatology, 2024 
 2024Muntyanu A, Milan R, Kaouache M, Ringuet J, Gulliver W, Pivneva I, Royer J, Leroux M, Chen K, Yu Q, Litvinov I, Griffiths CEM, Ashcroft DM, Rahme E, Netchiporouk E 
- 
                                                        Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) StudyDermatology and Therapy, 2024 
 2024Pinter A, Soliman AM, Pivneva I, Ghanbariamin R, Yang M, Truong B, Puig L, Lebwohl M 
- 
                                                        Treatment Discontinuation Patterns for Patients with Chronic Lymphocytic Leukemia in Real-World Settings: Results from a Multi-Center International StudyClinical Lymphoma, Myeloma & Leukemia, 2023 
 2023Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR 
- 
                                                        Disease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticariaThe World Allergy Organization Journal, 2023 
 2023Soong W, Patil D, Pivneva I, Signorovitch J, Wells MA, Balp MM, Kuruvilla M 
- 
                                                        Surgical Treatment Patterns, Healthcare Resource Utilization, and Economic Burden in Patients with Tenosynovial Giant Cell Tumor Who Underwent Joint Surgery in the United StatesJournal of Health Economics and Outcomes Research, 2022 
 2022
- 
                                                        Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World DataDermatology and Therapy, 2022 
 2022Pivneva I, Balp MM, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Royer J, Liang Y, Cornwall T, Pan J, Danyliv A, McKenna SJ, Marsland AM, Soong W 
- 
                                                        Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updatesLeukemia & Lymphoma, 2021 
 2021Atallah EL, Sadek I, Maegawa R, Cao X, Latrémouille-Viau D, Pivneva I, Rossi C, Guérin A, Kota V 
- 
                                                        Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache CentersNeurology and Therapy, 2021 
 2021Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S, Hogan R, Blumenfeld A, Schim J, Feoktistov A, Carnes K, Bensink M, Wu EQ, Chou DE, Chandler D 
- 
                                                        The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United StatesJournal of Occupational and Environmental Medicine, 2021 
 2021Lin F, Ionescu-Ittu R, Pivneva I, Wynant W, Shi S, Wu EQ, Kwong WJ, Abraham JA 
- 
                                                        Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspectiveLeukemia & Lymphoma, 2019 
 2019Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL 
- 
                                                        Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care SystemAmerican Journal of Ophthalmology, 2019 
 2019Dana R, Bradley JL, Guerin A, Pivneva I, Stillman IO, Evans AM, Schaumberg DA 
- 
                                                        Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1Advances in Therapy, 2019 
 2019Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM 
- 
                                                        Dry eye disease ranking among common reasons for seeking eye care in a large US claims databaseClinical Ophthalmology, 2019 
 2019Bradley JL, Stillman IO, Pivneva I, Guerin A, Evans AM, Dana R 
- 
                                                        The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data AnalysisDermatology and Therapy. 2018 Dec;8(4):557-569 
 2018Kimball AB, Sundaram M, Gauthier G, Guérin A, Pivneva I, Singh R, Ganguli A 
- 
                                                        Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United StatesAdvances in Therapy, 2018 Oct;35(10):1671-1685 
 2018Seiter K, Latrémouille-Viau D, Guérin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ 
- 
                                                        Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapyLung Cancer. May 2018;119:112-119 
 2018Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R 
- 
                                                        Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims DatabaseJournal of Clinical Psychiatry. Feb 20 2018;79(2) 
 2018Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE 
- 
                                                        Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung CancerClinical Lung Cancer. Nov 2017;18(6):640-650 e642 
 2017Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Pivneva I, Borghaei H 
- 
                                                    June 18, 2024
- 
                                                    December 1, 2023
- 
                                                    June 27, 2023
- 
                                                    March 29, 2022
